Call Text Chat Email Refer a Patient Join a Study

Search

MotherToBaby

Medications and More during pregnancy and breastfeeding

Psoriasis and Psoriatic Arthritis

Selected References:

  • Bandoli G, et al. 2010 Potentially modifiable risk factors for adverse pregnancy outcomes in women with psoriasis. Br J Dermatol; 163(2):334-339. 
  • Ben-David G, et al. 2008. Pregnancy outcome in women with psoriasis. J Reprod Med; 53(3):183-187.  
  • Berman M, et al. 2018. The effect of pregnancy on disease activity in patients with psoriatic arthritis. J Rheumatol; 45(12):1651-1655. 
  • Bobotsis R, et al. 2016. Psoriasis and adverse pregnancy outcomes: a systematic review of observational studies. Br J Dermatol; 175(3):464-472.  
  • Bröms G, et al. 2018. Effect of maternal psoriasis on pregnancy and birth Outcomes: A population-based cohort study from Denmark and Sweden. Acta Derm Venereol; 98(8):728-734. 
  • Butler DC, et al. 2014. Safety of dermatologic medications in pregnancy and lactation: Part II. Lactation. J Am Acad Dermatol; 70(3):417.e1-10; quiz 427.  
  • Caldarola G, et al. 2017. Untreated psoriasis impairs male fertility: A case-control study. Dermatology; 233(2-3):170-174. 
  • Carman WJ, et al. 2017. Pregnancy and infant outcomes including major congenital malformations among women with chronic inflammatory arthritis or psoriasis, with and without etanercept use. Pharmacoepidemiol Drug Saf; 26(9):1109-1118. 
  • Cohen-Barak E, et al. 2011. Pregnancy outcomes in women with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol; 25(9):1041-1047.  
  • Eudy AM, et al. 2020. Pregnancy outcomes, fertility, and family planning in with psoriatic arthritis. Obstet Med; 13(2)70-75. 
  • Gladman DD, et al. 2005. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis; 64 Suppl 2:ii14-17. 
  • Harder E, et al. 2014. No increased risk of fetal death or prolonged time to pregnancy in women with psoriasis. Invest Dermatol; 34(6):1747-1749. 
  • Huerta C, et al. 2007. Incidence and Risk Factors for Psoriasis in the General Population. Arch Dermatol; 143(12):1559-1565. 
  • Johansen CB, et al. 2022. Psoriasis and adverse pregnancy outcomes: A nationwide case-control study in 491,274 women in Denmark. JAAD; Int  7: 146–155. 
  • Kerola AM, et al. 2024. Patterns of reproductive health in inflammatory rheumatic diseases and other immune-mediated diseases: a nationwide registry study. Rheumatology (Oxford). keae122. PMID: 38503536. 
  • Kimball AE et al. 2021. Pregnancy Outcomes in Women With Moderate-to-Severe Psoriasis From the Psoriasis Longitudinal Assessment and Registry (PSOLAR) JAMA Dermatol; 157(3): 1–6. 
  • Meissner Y, et al. 2021. Pregnancy in women with psoriatic arthritis: A systematic literature review of disease activity and adverse pregnancy outcomes. Semin Arthritis Rheum; 51(3):530-538. 
  • Meserve J, et al. 2021. Paternal Exposure to Immunosuppressive and/or Biologic Agents and Birth Outcomes in Patients with Immune-Mediated Inflammatory Diseases. Gastroenterology; 161(1):107-115. 
  • Lima XT, et al. 2012. The impact of psoriasis on pregnancy outcomes. J Invest Dermatol; 132(1):85-91.  
  • McMullan P, et al. 2024. Safety of dermatologic medications in pregnancy and lactation: An Update – Part I: Pregnancy. J Am Acad Dermatol; S0190-9622(24)00109-9.  
  • Murase JE, et al. 2005. Hormonal effect on psoriasis in pregnancy & post-partum. Arch Dermatol; 141(5):601-606. 
  • Murase JE, et al. 2014. Safety of dermatologic medications in pregnancy and lactation: Part I. Pregnancy. J Am Acad Dermatol; 70(3):401.e1-14. 
  • Ostensen M. 1992. The effect of pregnancy on ankylosing spondylitis, psoriatic arthritis, and juvenile rheumatoid arthritis. Am J Reprod Immunol; 28(3-4):235-237. 
  • Polachek A, et al. 2018. Outcome of pregnancy in women with psoriatic arthritis compared to healthy controls. Clinic Rheum; 38: 895-902. 
  • Rademaker M, et al. 2018. Psoriasis in those planning a family, pregnant or breast-feeding. The Australasian Psoriasis Collaboration. Australas J Dermatol; 59(2):86-100. 
  • Rahmati S, et al. 2023. Impact of maternal psoriasis on adverse maternal and neonatal outcomes: a systematic review and meta-analysis. BMC Pregnancy Childbirth; 23(1):703.  
  • Raychaudhuri SP, et al. 2003. Clinical course of psoriasis during pregnancy. Int J Dermatol; 42(7):518-20. 
  • Remaeus K, et al. 2019. Maternal and infant pregnancy outcomes in women with psoriatic arthritis: a Swedish nationwide cohort study. BJOG; 126(10):1213-1222. 
  • Secher AEP, et al. 2025. Preterm birth in women with psoriatic arthritis: what are the risks and risk factors? A collaborative cohort study from Sweden, Denmark and Norway. RMD Open; 11(4):e005614.  
  • Seeger JD, et al. 2007. Pregnancy and pregnancy outcome among women with inflammatory skin diseases. Dermatol; 214(1)32-39.  
  • Smith C, et al. 2020. Birth outcomes and disease activity during pregnancy in a prospective cohort of women with psoriatic arthritis and ankylosing spondylitis. Amer Col Rheum; 72(7):1029-1037 
  • Tuğrul Ayanoğlu B, et al. 2018. Diminished ovarian reserve in patients with psoriasis. Taiwan J Obstet Gynecol; 57(2):227-230.  
  • Ursin K, et al. 2018. Disease activity of psoriatic arthritis during and after pregnancy: A prospective multicenter study. Arthritis Care Res (Hoboken); 71(8):1092-1100. 
  • Yaghi M, et al. 2024. Safety of Dermatologic Medications in Pregnancy and Lactation: An Update – Part II: Lactation. J Am Acad Dermatol; S0190-9622(24)00110-5.  
  • Yang YW, et al. 2011. Psoriasis and pregnancy outcomes: a nationwide population-based study. J Am Acad Dermatol; 64(1):71-77.  
  • Yiu ZZ, et al. 2014. Safety of biological therapies for psoriasis: effects on reproductive potential and outcomes in male and female patients. Br J Dermatol; 171(3):485-491. 
  • Yiu ZZ, et al. 2015. Safety of conventional systemic therapies for psoriasis on reproductive potential and outcomes. J Dermatolog Treat; 30:1-6.  

This website is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $1,200,000 with zero percentage financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, HRSA, HHS, or the U.S. Government.